Absence of transforming growth factor-β type II receptor is associated with poorer prognosis in HER2-negative breast tumours

Abstract

Background: The clinical relevance of transforming growth factor-beta (TGF-β)-signalling pathway in breast carcinomas (BCs) remained elusive. This study aimed to evaluate the prognostic value of TGF-β1 and transforming growth factor-beta type II receptor (TGF-bRII) expression levels in tumour cells and their association with the established biomarkers in BC. Patients and methods: In 324 BC from patients with long-term follow-up, the TGF-β1 and TGF-βRII transcript and protein expression levels were assessed. Results: TGF-β1 and TGF-βRII down-expression was significantly associated with BC. Negative TGF-β1 and TGFbRII protein status was associated with the development of distant metastasis (P = 0.003 and P = 0.029, respectively). In multivariate analysis, TGF-β1-positive tumours were associated with increased disease-free survival (DFS) [hazard ratio (HR) = 0.489, P = 0.003]. TGF-bRII positivity was an independent prognostic factor for DFS (HR = 0.439, P = 0.001) and overall survival (OS) (HR = 0.409, P = 0.003) in human epidermal growth factor receptor2 (HER2)-negative patients. Absence of TGF-b1 and TGF-bRII proteins in breast tumour cells was significantly associated with metastasis development. Conclusions: To the best of our knowledge, this is the first report indicating the relevance of HER2 status in discriminating TGF-bRII as a prognostic marker for DFS and OS in human BC. These data indicate that TGF-βRII protein analysis in tumour cells could be introduced in clinical practice as additional prognostic biomarker in HER2-negative BC. © The Author 2009. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org.